The use of statistical tests to assess potential correlations between molecular parameters —specifically MMR/MSI status and KRAS gene mutational status— and the categories of CDX2 expression in colon cancer is hindered by inconsistencies in the evaluation of these biomarkers across all oncological stages. The gene discussed is KRAS; the disease is colonic neoplasm.